MentionFox
Home › Acquisitions › Eli Lilly and Company
Completed acquisition · SEC Form 8-K, Item 2.01

Ventyx Biosciences, Inc. acquired by Eli Lilly and Company

Before you sign with, sell to or invest in Ventyx Biosciences, Inc.

MentionFox check on Ventyx Biosciences, Inc.: only 1 source on file so far (checked 6 November 2026). Run a full check before you rely on it. mentionfox.com/c/acquisitions/eli-lilly-and-ventyx-biosciences-2026-03-04

Check Ventyx Biosciences, Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Ventyx Biosciences, Inc.?

From Ventyx Biosciences, Inc.'s Form 8-K of 2026-03-04, quoted and linked below.

Ventyx Biosciences, Inc. was acquired by Eli Lilly and Company on March 4, 2026, according to the Form 8-K Ventyx Biosciences, Inc. filed with the SEC. The filing states a price of $1.2 billion. Each Ventyx Biosciences, Inc. share was converted into the right to receive $14.00 in cash (Form 8-K, March 4, 2026).

2 companies announced an acquisition this week, 1 had other signals.

Companies in an acquisition this week, and the deal. Before you unlock: the company, the deal and what is inside. After: every way we found to reach the company, and anyone a source names. A team joining the buyer is labelled only when the filing itself says so.

InMed Pharmaceuticals Inc.agreed to acquire Mentari
Liberty Capital Corp/NVagreed to acquire Q Gateway Intermediate Holdings, LLC
Check one company free All companies that announced an acquisition this week

Competing with, selling to or investing in Eli Lilly and Company after this deal? See the free Snapshot first.

Free to see. No signup.

Eli Lilly and Company completed its acquisition of Ventyx Biosciences, Inc. on 2026-03-04, according to the Form 8-K Ventyx Biosciences, Inc. filed with the SEC on 2026-03-04. The filing states a price of $1.2 billion. Ventyx Biosciences, Inc. filed the report because the deal made it part of Eli Lilly and Company.

AcquirerEli Lilly and Company
AcquiredVentyx Biosciences, Inc.
Completed2026-03-04
Price stated in the filing$1.2 billion
Reported byVentyx Biosciences, Inc. (VTYX), the company acquired
FilingForm 8-K, filed 2026-03-04

Want the whole picture on Eli Lilly and Company?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Eli Lilly and Company: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Eli Lilly and Company covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

What the filing says

On March 4, 2026 (the "Closing Date"), pursuant to the Merger Agreement, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

How much did Eli Lilly and Company pay for Ventyx Biosciences, Inc.?

The aggregate consideration that was or will be paid to stockholders and other equity holders of the Company in connection with the Merger is approximately $1.2 billion, without giving effect to related transaction fees and expenses.

More from the filing

As previously disclosed in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on January 7, 2026, Ventyx Biosciences, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated January 7, 2026, with Eli Lilly and Company, an Indiana corporation ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation, a Delaware corporation ("Merger Sub").
Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Common Stock") issued and outstanding immediately prior to the Effective Time, was converted into the right to receive $14.00 per share, payable to the holder in cash, without interest (the "Common Merger Consideration Amount") and less any applicable tax withholding.

Quoted from Ventyx Biosciences, Inc.'s Form 8-K.

Other acquisitions by Eli Lilly and Company

CompletedAcquiredPrice stated
2025-11-07Adverum Biotechnologies, Inc.Not stated
2026-09-11AtaiBeckley Inc.Not stated
Selling to Eli Lilly and Company, or weighing an offer there?

Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.

Order Full Report on Eli Lilly and Company
Not ready to order?

Look up Eli Lilly and Company first. Finding the company and seeing how much is on record uses no credits.

Look up Eli Lilly and Company

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.

Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.

More on Ventyx Biosciences, Inc.

Cite this page

Permanent URL: https://mentionfox.com/acquisitions/eli-lilly-and-ventyx-biosciences-2026-03-04
Last updated 2026-11-06
Primary record: SEC filing
Ventyx Biosciences, Inc. acquired by Eli Lilly and Company for $1.2 billion: completed 2026-03-04. MentionFox, 2026-11-06. https://mentionfox.com/acquisitions/eli-lilly-and-ventyx-biosciences-2026-03-04